Experienced in Thrombocytopenia

Mario J. Bargetzi

Aarau, AG, CH 
Experienced in Thrombocytopenia
Aarau, AG, CH 
OverviewLocationsClinical Research

Overview

Mario Bargetzi practices in Aarau, Switzerland. Mr. Bargetzi is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Thrombocytopenia.

Gender
Male

Locations

Aarau, AG, Switzerland
Other Locations
Basel, BS, Switzerland
Bern, BE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drugs: Ibrutinib, Bortezomib
Study Phase: Phase 1/Phase 2
Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland
Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland
Enrollment Status: Terminated
Publish Date: October 14, 2021
Intervention Type: Diagnostic test
View 2 Less Clinical Trials

60 Total Publications

Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria-a pilot study (ePRO-AA-PNH).
Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria-a pilot study (ePRO-AA-PNH).
Journal: Annals of hematology
Published: May 24, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bargetzi's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile